Dapsone - the treatment of infectious and inflammatory diseases in dermatology

International Journal of Antimicrobial Agents

Volumn 7, Issue 3, 1996, Pages 187-192

  Grunwald, Marcelo H ^a   Amichai, Boaz ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Clinical applications; Dapsone; Monitoring guidelines; Pharmacology

Indexed keywords

DAPSONE; PROBENECID; RIFAMPICIN;

AGRANULOCYTOSIS; AUTOIMMUNITY; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG THERAPY; HEMOLYSIS; HUMAN; HYPERSENSITIVITY REACTION; LEPROSY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; SKIN INFLAMMATION;

EID: 0029774558     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(96)00321-4     Document Type: Article

References (87)

1. Champion RH, Burton JJ, Ebling FJG, eds. Dapsone. In: Text-book of Dermatology, 5th edn. Oxford: Blackwell Scientific Publications, 1992;2958-2959.
2. Lang PG. Sulfones and sulfonamides in dermatology. J Am Acad Dermatol 1979;1:479-492.
3. Sulzberger MB. Acrodermatitis continua pustulosa (Hallopeau) treated with sulfapyridine. Arch Dermatol Syph 1939;40:1019-1021.
4. Costello M. Dermatitis herpetiformis treated with sulfapyridine. Arch Dermatol Syph 1940;41:134.
5. Coleman MD. Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance. Br J Dermatol 1993;129:507-513.
6. Reynolds JEF, Parfitt K, eds. Dapsone. In: Martindale. The Extra Pharmacopoeia. 30th edn. London: The Pharmaceutical Press, 1993:157-158.
7. Wolverton SE. Monitoring for adverse effects from systemic drugs using in dermatology. J Am Acad Dermatol 1992;26:661-679.
8. Hiran S, Pande TK, Rizvi SA et al. Dapsone syndrome. J Assoc Physicians India 1994;42:497.
9. Puri AS, Gupta R, Ghoshal UC et al. Hepatic injury in sulfone sydrome: hepatitis or cholestasis? Indian J Gastroenterol 1995;14:20.
10. Todd P, Samaratunga IR, Pembroke A. Screening for glucose-6-phosphate dehydrogenase (G6PD) deficiency prior to dapsone therapy. Clin Exp Dermatol 1994;19:217-218.
11. Manfredi G, de Panfilis G, Zampetti M et al. Studies on dapsone induced haemolytic anaemia. I. Methaemoglobin production and G-6-PD activity in correlation with dapsone dosage. Br J Dermatol 1979;100:427-432.
12. Meyerson MA, Cohen PR. Dapsone-induced aplastic anemia in a woman with bullous systemic lupus erythematosus. Mayo Clin Proc 1994;69:1159-1162.
13. Woodbury GR, Fried W, Ertle JO et al. Dapsone-associated agranulocytosis and severe anemia in a patient with leukocytoclastic vasculitis. J Am Acad Dermatol 1993;28:781-783.
14. Hornsten P, Keisu M, Wilholm BE. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990;126:919-922.
15. Ognibene AJ. Agranulocytosis due to dapsone. Ann Inter Med 1970;72:521-524.
16. Friman G, Nystrom-Rosander C, Jonsell G et al. Agranulocytosis associated with malaria prophylaxis with malporim. Br Med J 1983;286:1244-1245.
17. Revuz J, Hornac P. Side effects of treatment with sulphones. Larc Med 1981;1:68-70.
18. Hoffbrand BE. Dapsone-induced renal papillary necrosis. Br Med J 1978;1:78.
19. Stone SP, Goodwin RM. Dapsone-induced jaundice. Arch Dermatol 1978;114:947.
20. Dhanapaul S. DDS-induced photosensitivity with reference to six case reports. Leprosy Rsv 1989;60:147-150.
21. Patki AH, Mehta JM. Dapsone-induced erythroderma with Beau's lines. Leprosy Rev 1989;60:274-277.
22. Maurus JN. Hansen's disease in pregnancy. Obstet Gynecol 1978;52:22-25.
23. Kingham JGC, Swain P, Swarbrich ET et al. Dapsone and severe hypoalbuminemia. Lancet 1979;2:662-664.
24. Prussick R, Ali MAM, Rosenthal D et al. The protective effect of vitamin E on the haemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol 1993;128:210-213.
25. Arnold HL, Odom RB, James WD, eds. Dermatitis herpetiformis. In: Andrew's Diseases of the Skin, 8th edn. Philadelphia: WB Saunders, 1990;552-555.
26. Arnold HL, Odom RB, James WD, eds. Leprosy. In: Andrew's Diseases of the Skin, 8th edn. Philadelphia: WB Saunders, 1990:389-404.
27. Jenkins D, Papp K, Jakubovic HR et al. Leprotic involvement of peripheral nerves in the absence of skin lesions. Case report and literature review. J Am Acad Dermatol 1990;23:1023-1026.
28. Rogers RS, Muller SA. Treatment of actinomycetoma with dapsone. Arch Dermatol 1974;109:529-534.
29. Hironaga M, Mochizuki T, Watanabe S. Acute primary cutaneous nocardiosis. J Am Acad Dermatol 1990;23:399-400.
30. Nair KK, State K. Clinical trial of diamino-diphenylsulfone (DDS) in nasal and nosopharyngeal rhinosporidiosis. Laryngoscope 1979;89:291-295.
31. Dogra J, Lal BB, Misra SN. Dapsone in the treatment of cutaneous leishmaniasis. Int J Dermatol 1986;25:398-400.
32. Shanks GD, Karwacki JJ, Singharaj P. Malaria prophylaxis during military operations in Thailand. Military Med 1989;154:500-502.
33. Montgomery AB. Prophylaxis of Pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus type 1. Semin Respir Infect 1989;4:311-317.
34. Opravil M, Pechere M, Lazzarin A et al. Dapsone/pyrimethamine may prevent mycobacterial disease in immuno-suppressed patients infected with human immunodeficiency virus. Clin Infect Dis 1995;20:244-249.
35. Hardy WD. Prophylaxis of AIDS-related opportunistic infections (OIs). AIDS Clin Rev 1989;125-150.
36. Hasson A, Gutierrez MC, Martin L et al. Dermatitis herpetiformis and AIDS-relatad complex. J Am Acad Dermatol 1990;22:1117-1119.
37. Leitao EA, Bernhard JD. Perimenstrual nonvesicular Dermatitis herpetiformis. J Am Acad Dermatol 1990;22:331-334.
38. Kalaher KM, Scott DW. Subcorneal pustular dermatosis in dogs and human beings: comparative aspects. J Am Acad Dermatol 1990;22:1023-1028.
39. Walker KD, Badame AJ. Erythema elevatum diutinum in a patient with Crohn's disease. J Am Acad Dermatol 1990;22:948-952.
40. LeBoit PE, Cockerell CJ. Nodular lesions of Erythema elevatum diutinum in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1993;28:919-922.
41. Yenning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol 1992;26:585-589.
42. Yenning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol 1989;120:83-92.
43. Ahmed AR, Kurgis BS, Rogers RS. Cicatricial pemphigoid. J Am Acad Dermatol 1991;24:987-1001.
44. Esterly NB, Furey NL, Kushner BS et al. Chronic bullous disease of childhood. Arch Dermatol 1977;113:42-46.
45. Collier PM, Kelly SE, Wojnarowska F. Linear IgA disease and pregnancy. J Am Acad Dermatol 1994;30:407-411.
46. McCuaig CC, Chan LS, Woodley DT et al. Epidermolysis bullosa acquisita in childhood. Differentiation from hereditary epidermolysis bullosa. Arch Dermatol 1989;125:944-949.
47. Hocking DR. Neonatal hemolytic disease due to dapsone. Med J Aust 1968;1:1130-1131.
48. Lyde CB, Cox SE, Cruz PD. Pemphigus erythematosus in a five-year-old child. J Am Acad Dermatol 1994;31:906-909.
49. Goldberg NS, DeFeo C, Krishenbaum N. Pemphigus vulgaris and pregnancy: risk factors and recommendations. J Am Acad Dermatol 1993;28:877-879.
50. Basset N, Guillot B, Michel B et al. Dapsone as initial treatment in superficial pemphigus. Report of nine cases. Arch Dermatol 1987;123:783-785.
51. Sire JD, Johnson BL. Benign familial chronic pemphigus treated with dapsone. Arch Dermatol 1971;103:262-265.
52. Duhra P, Paul CJ. Continuous erythema multiforme clearing on dapsone. Br J Dermatol 1988;118:731.
53. Krahe J, Galal O, Kordass U et al. Epidermolysis bullosa atrophicans gravis. Report of a therapeutic trial with dapsone. Monatsschr Kinderheilkd 1988;136:140-142.
54. Wozel G, Thiele B. Urticaria vasculitis and sulfone, a case report. Z Hautkr 1987;62:407-409.
55. Nurnberg W, Grabbe J. Czarnezki BM. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifiline. Acta Derm Venereol 1995;75:54-56.
56. Fredenberg MF, Malkinson FD. Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases. J Am Acad Dermatol 1987;16:772-778.
57. Smiley JD, Moore SE Jr. Immune-complex vasculitis: role of complement and IgG-Fc receptor functions. Am J Med Sci 1989;298:267-277.
58. Sarma PS. Dapsone in Henoch-Schonlein purpura. Postgrad Med J 1994;70:464-465.
59. Guillevin L. Treatment of polyarteritis nodosa with dapsone. Scand J Rheumatol 1986;15:95-96.
60. Jackly WK. Behcet's disease in South Africans blacks: report of five cases. J Am Acad Dermatol 1994;30:869-873.
61. Hamza M, Hamzaoui K, Ayed K. Treatment of Behcet's disease with dapsone. Clin Rheumatol 1989;8:113-114.
62. von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol 1994;31:535-556 [quiz 557-560].
63. Kuan YZ, Chiou HT, Chang HC et al. Intraepidermal neutrophilic Ig dermatosis. J Am Acad Dermatol 1990;22:917-919.
64. Barranco VP, Minor DB, Solomon H. Treatment of relapsing polychondritis with dapsone. Arch Dermatol 1976; 112:1286-1288.
65. Job-Deslandre C, Menkes CJ. Treatment of rheumatoid polyarthritis with dapsone. A controlled study versus placebo. Rev Rhum Mal Osteoartic 1989;56:313-316.
66. Lindskov R, Reymann F. Dapsone in the treatment of cutaneous lupus erythematosus. Dermatologica 1986;172:214-217.
67. Yamada Y, Dekio S, Jidoi J et al. Lupus erythematosus profundus-report of a case treated with dapsone. J Dermatol 1989;16:379-382.
68. Faulhaber G, Lechner W. Urticaria-vasculitis with bullous eruptions in visceral lupus erythematosus. Z Hautkr 1987;62:839-840, 843-844.
69. Reinitz E, Aversa A. Long-term treatment of temporal arteritis with dapsone. Am J Med 1988;85:456-457.
70. Wozel G. Recurrent nodular panniculitis in alpha 1-antitrypsin deficiency. Successful dapsone therapy. Hautartz 1994;45:580-581.
71. Roth DE, Schikler KN, Gallen JP. Annular atrophic connective tissue panniculitis of the ankles. J Am Acad Dermatol 1989;21:1152-1156.
72. Taieb A, Bassan-Andrieu L, Maleville J. Eosinophilic pustulosis of the scalp in childhood. J Am Acad Dermatol 1992;27:55-60.
73. Lee MW, Nixon RL. Eosinophilic cellulitis case report: treatment options. Australas J Dermatol 1994;35:95-97.
74. Perry HO, Brunsting LA. Pyoderma gangrenosum. Arch Dermatol 1957;75:380-386.
75. van de Kerkhof PC. On the efficacy of dapsone in granuloma faciale. Acta Derm Venereol 1994;74:61-62.
76. Andrews GC, Domonkos AN, Post CF. Treatment of acne vulgaris. J Am Med Assoc 1951;146:1107-1113.
77. Ismail R. Acne fulminans with dapsone induced haemolysis: a case report. Med J Malaysia 1987;42:124-126.
78. Kumar B, Kaur I, Bhattacharya M. Dapsone in lichen planus. Acta Dermatol Venereol 1994;74:334.
79. Camisa C, Neff JC, Rossana T et al. Bullous lichen planus: diagnosis by indirect immunofluorescence and treatment with dapsone. J Am Acad Dermatol 1986;14:464-469.
80. Nakamura S, Nishihara K., Nakayama K. et al. Febrile ulceronecrotic Mucha-Habermann's disease and its successful therapy with DDS. J Dermatol 1986;13:381-384.
81. Macmillian AL, Champion RH. Generalized pustular psoriasis treated with dapsone. Br J Dermatol 1973;88:183-185.
82. Czarnecki DB. The response of generalized granuloma annulare to dapsone. Acta Derm Venereol 1986;66:82-87.
83. Binder LS. Acute arthropod envenomation. Incidence, clinical features and management. Med Toxicol Adverse Drug Exp 1989;4:163-173.
84. Rustin MH, Bunker CB, Levene GM. Follicular mucinosis presenting as acute dermatitis and response to dapsone. Clin Exp Dermatol 1989;14:382-384.
85. Guillot B, Guilhou JJ, Meynadier J. Treatment of Kaposi's disease with dapsone. Presse Med 1986;15:2025.
86. Joyce AP, Horn TD, Anhalt GJ. Prurigo pigmentosa. Report of a case and review of the literature. Arch Dermatol 1989;125:1551-1554.
87. Palungwachira P. Infantile acropustulosis. Australas J Dermatol 1989;30:97-100.